The Zhitong Finance App learned that CITIC Lyon released a research report stating that it believes that Cinda Biotech (01801.HK) is one of the most differentiated biopharmaceutical companies in China, combining industry-leading commercial execution with an expanding product portfolio. The bank raised its target price from HK$146.1 to HK$152, maintaining the “better than the market” rating.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.